Apogee Therapeutics secures up to $800 million royalty deal with Blackstone Life Sciences to fund Phase 3 trials of eczema drug zumilokibart.
The biggest question Apogee Therapeutics CEO Michael Henderson gets from investors?
“These are big markets, this takes a lot of capital — are you just going …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Apogee Stock Slides After Blackstone Financing Deal And Positive Drug Data - Apogee Therapeutics (NASDAQ:
Apogee eczema drugs gets Blackstone backing, heads to Phase 3
Five biotech news updates to stay on top of today
ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary
Apogee shares fell after announcing a $1.3 billion Blackstone financing deal alongside positive Phase 2 eczema drug results.
The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which…
Blackstone Life Sciences is putting $250 million to work on a little-known biotech seeking to drastically reduce the number of…
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere,…
Full-Life Technologies gets $150M; Quince finds a new life; China biotech gets $50M; SERB Pharmaceuticals buys rights to Hansa…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
